Airway Therapeutics Raises $50 Million
Airway Therapeutics, a company focused on developing innovative therapies for respiratory diseases, has successfully raised $50 million in its Series E-2 funding round. The funding round, which took place on August 25, 2026, was structured as a SAFE (Simple Agreement for Future Equity) but did not have a lead investor or specified investors.
Company Overview
Based in Atlanta, Georgia, Airway Therapeutics is dedicated to addressing unmet medical needs in the field of respiratory health. The company is working on therapeutic solutions that aim to improve the treatment and management of various respiratory conditions.
Use of Funds
Although specific plans for the newly acquired funds were not detailed in the announcement, companies in similar stages typically allocate such investments towards clinical trials, research and development, and scaling their operations. Airway Therapeutics is expected to use this capital to further its product development and potentially expand its market reach.
Conclusion
The successful completion of this funding round marks a significant milestone for Airway Therapeutics, as it continues to pursue advancements in respiratory care. The funds will likely support the company in its efforts to bring innovative treatments to patients in need.